Clinicopathological Analysis of Rhabdomyosarcoma Patients Undergone Radiotherapy in Two Referral Hospitals in West Java
DOI:
https://doi.org/10.59188/eduvest.v4i8.1307Keywords:
Clinicopathological, Rhabdomyosarcoma, RadiotherapyAbstract
Rhabdomyosarcoma (RMS) is a type of malignant soft tissue neoplasm that develops from mesenchymal cells of skeletal muscle origin. This condition comprises multiple subtypes with distinct histologic characteristics. While cases of RMS are uncommon overall, they are more frequently diagnosed in children, although adults can also be affected. Treatment options for RMS include radiotherapy, with the specific therapy and dosage determined according to the IRS Group classification system. This study was conducted by collecting secondary data of RMS patients from the medical records consecutively who had been diagnosed and received radiotherapy. The data resources were from Radiotherapy Department and Anatomical Pathology Department of RSUP Dr. Hasan Sadikin Bandung and RSUD Al-Ihsan Bandung, between 2017 and 2023. A total of 31 patients were documented. The age of patients ranging from 3 to 66 years old (mean=34.6), with each of age group (children, adult, elderly) consists of 10, 10, and 11 patients respectively. Based on histologic subtype, most cases of RMS recorded are embryonal subtype (n=10) followed by alveolar RMS and pleomorphic RMS with 6 patients each. The extremities were the most common location (n=13) followed by the head and neck region (n=10). After radiotherapy, 20 cases were accounted as radiosensitive and 11 cases were radioresistant. Thirty one patients with rhabdomyosarcoma have received radiotherapy at two referral hospitals in Bandung between 2017-2023. The tumors in pediatric and elderly patients were more sensitive to therapy. Pleomorphic RMS were the most sensitive subtype, and the larger a tumor, the more sensitive it can be.
References
Ahmad Z, & et al. (2015). Rhabdomyosarcoma - an epidemiological and hjistopathologic study of 277 cases from a major tertiary care center in Karachi, Pakistan. Asian Pac J Cancer Prev, 16(2), 757–760.
American Cancer Society. (n.d.). Key statistics for rhabdomyosarcoma. Retrieved February 12, 2024, from https://www.cancer.org/cancer/types/ rhabdomyosarcoma/about/key-statistics.html
Baskar R, & et al. (2014). Biological response of cancer cells to radiation treatment. Front Mol Biosci, 1, 24.
Bergamaschi L, & et al. (2019). Rhabdomyosarcoma in adults: analysis of treatment modalities in a prospective single center series. Med Oncol, 36(7), 59.
Brunicardi FC. (2019). Schwartz’s principle of surgery (7th ed.). McGraw-Hill.
Camero S, & et al. (2022). Radioresistance in rhabdomyosarcomas: Much more than a question of dose. Front Oncol, 12, 1016894.
European paediatric Soft tissue sarcoma Study Group (EpSSG). (2012). A protocol for non metastatic rhabdomyosarcoma (RMS 2005, Ed.).
Frankart A, Breneman JC, & Pater LE. (2021). Radiation therapy in the treatment of head and neck rhabdomyosarcoma. Cancers (Basel), 13(14), 3567.
Goldblum JR, Folpe AL, & Weiss, S. (2020). Enzinger & Weiss’s. Soft tissue tumors (7th ed.). Elsevier.
Goldblum JR, Lamps LW, McKenney JK, & Myers JL. (2018). Surgical Pathology (11th ed.). Elsevier.
Hornick JL. (2019). Practical soft tissue pathology (2nd ed.). Elsevier.
Khosla D, & et al. (2015). Adult rhabdomyosarcoma: Clinical presentation, treatment, and outcome. J Cancer Res Ther, 11(4), 830–834.
Leuschner I, & et al. (2003). p53 and mdm-2 expression in rhabdomyosarcoma of childhood and adolescence: clinicopathologic study by the Kiel Pediatric Tumor Registry and the German Cooperative Soft Tissue Sarcoma Study. Pediatr Dev Pathol, 6(2), 128–136.
Lindberg MR. (2019). Diagnostic pathology. Soft tissue tumors (3rd ed.). Elsevier.
Martin-Giacalone BA, Weinstein PA, Plon SE, & Lupo PJ. (2021). Pediatric Rhabdomyosarcoma: Epidemiology and genetic susceptibility. J Clin Med, 10(9), 2028.
McEvoy MT, & et al. (2023). Pediatric rhabdomyosarcoma incidence and survival in the United States: An assessment of 5656 cases, 2001–2017. Cancer Med, 12(3), 3644–3656.
Raney RB, & et al. (2001). The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma, 5(1), 9–15.
SIstem Infornmasi Rumah Sakit. (2023). Data sarkoma RSUP Dr. Hasan Sadikin Bandung.
Wang X, & et al. (2020). Characteristics and prognosis of embryonal rhabdomyosarcoma in children and adolescents: An analysis of 464 cases from the SEER database. Pediatr Investig, 4(4), 242–249.
World Health Organization. (2020). Soft tissue and bone tumours (WHO Classification of Tumours Editorial Board, Ed.; 5th ed.). International Agency for Research on Cancer.
Published
Issue
Section
License
Copyright (c) 2024 Muhammad Syah Misuari Sabirin, Hermin Aminah Usman, Anglita Yantisetiasti, Mas Adi Sunardi
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
